Dipartimento di Scienze Farmaceutiche 'P. Pratesi', Università degli Studi di Milano, via L. Mangiagalli 25, 20133 Milano, Italy.
Future Med Chem. 2011 Apr;3(5):567-97. doi: 10.4155/fmc.11.22.
Signal transducer and activator of transcription 3 (STAT3) is an oncogenic protein whose inhibition is sought for the prevention and treatment of cancer. In this review, the validated therapeutic strategy to block aberrant activity of STAT3 in many tumor cell lines is evaluated by presenting the most promising inhibitors to date. The compounds are discussed in classes based on their different mechanisms of action, which are critically explained. In addition, their future clinical development as anticancer agents is considered. Furthermore, the efforts devoted to the comprehension of the structure-activity relationships and to the identification of the biological effects are brought to attention. The synthetic and technological approaches recently developed to overcome the difficulties in the obtainment of clinically suitable drugs are also presented.
信号转导子和转录激活子 3(STAT3)是一种致癌蛋白,其抑制作用被认为是预防和治疗癌症的一种方法。在这篇综述中,通过介绍迄今为止最有前途的抑制剂,评估了阻断许多肿瘤细胞系中异常 STAT3 活性的经过验证的治疗策略。根据其不同的作用机制对化合物进行分类讨论,并对其进行了批判性的解释。此外,还考虑了它们作为抗癌药物的未来临床开发。此外,还提请注意为了理解结构-活性关系和确定生物效应而付出的努力。还介绍了最近为克服获得临床适用药物的困难而开发的合成和技术方法。